Accepted Manuscript

8-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population

George V. Papatheodoridis, Vana Sypsa, George Dalekos, Cihan Yurdaydin, Florian Van Boemmel, Maria Buti, John Goulis, Jose Luis Calleja, Heng Chi, Spilios Manolakopoulos, Alessandro Loglio, Spyros Siakavellas, Nikolaos Gatselis, Onur Keskın, Maria Lehretz, Savvoula Savvidou, Juan de la Revilla, Bettina E. Hansen, Anastasia Kourikou, Ioannis Vlachogiannakos, Kostantinos Galanis, Ramazan Idilman, Massimo Colombo, Rafael Esteban, Harry L.A. Janssen, Thomas Berg, Pietro Lampertico


PII: S0168-8278(18)30081-3

DOI: https://doi.org/10.1016/j.jhep.2018.01.031

Reference: JHEPAT 6852

To appear in: Journal of Hepatology

Received Date: 28 November 2017 Revised Date: 21 January 2018 Accepted Date: 28 January 2018



Please cite this article as: Papatheodoridis, G.V., Sypsa, V., Dalekos, G., Yurdaydin, C., Van Boemmel, F., Buti, M., Goulis, J., Luis Calleja, J., Chi, H., Manolakopoulos, S., Loglio, A., Siakavellas, S., Gatselis, N., Keskin, O., Lehretz, M., Savvidou, S., de la Revilla, J., Hansen, B.E., Kourikou, A., Vlachogiannakos, I., Galanis, K., Idilman, R., Colombo, M., Esteban, R., Janssen, H.L.A., Berg, T., Lampertico, P., 8-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population, *Journal of Hepatology* (2018), doi: https://doi.org/10.1016/j.jhep.2018.01.031

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

ACCEPTED MANUSCRIPT

8-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population

George V. Papatheodoridis¹, Vana Sypsa², George Dalekos³, Cihan Yurdaydin⁴, Florian Van Boemmel⁵, Maria Buti⁶, John Goulis⁷, Jose Luis Calleja⁸, Heng Chi⁹, Spilios Manolakopoulos¹⁰, Alessandro Loglio¹¹, Spyros Siakavellas¹, Nikolaos Gatselis³, Onur Keskin⁴, Maria Lehretz⁵, Savvoula Savvidou⁷, Juan de la Revilla⁸, Bettina E. Hansen⁹, Anastasia Kourikou¹⁰, loannis Vlachogiannakos¹, Kostantinos Galanis³, Ramazan Idilman⁴, Massimo Colombo¹², Rafael Esteban⁶, Harry L.A. Janssen^{9,13}, Thomas Berg⁵, Pietro Lampertico¹¹.

¹Department of Gastroenterology, Medical School of National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece; ²Department of Hygiene, Epidemiology & Medical Statistics, Medical School of National and Kapodistrian University of Athens, Athens, Greece; ³Department of Internal Medicine, Thessalia University Medical School, Larissa, Greece; ⁴Department of Gastroenterology, University of Ankara Medical School, Ankara, Turkey; ⁵Section of Hepatology, Clinic for Gastroenterology and Rheumatology, University Clinic Leipzig, Germany; ⁶Hospital General Universitario Valle Hebron and Ciberehd, Barcelona, Spain; ⁷4th Department of Internal Medicine, Aristotle University of Thessaloniki Medical School, Thessaloniki, Greece; ⁸Hospital U Puerta de Hierro, IDIPHIM CIBERehd, Madrid, Spain; ⁹Department of Gastroenterology & Hepatology, Erasmus MC, University Medical Center, Rotterdam, Netherlands; ¹⁰2nd Department of Internal Medicine, Medical School of National and Kapodistrian University of

Download English Version:

https://daneshyari.com/en/article/8728959

Download Persian Version:

https://daneshyari.com/article/8728959

<u>Daneshyari.com</u>